Top

BMC Medicine

Published in:

Open Access 01-12-2022 | Research article

The impact of local vaccine coverage and recent incidence on measles transmission in France between 2009 and 2018

Authors: Alexis Robert, Adam J. Kucharski, Sebastian Funk

Published in: BMC Medicine | Issue 1/2022

Abstract

Background

Subnational heterogeneity in immunity to measles can create pockets of susceptibility and result in long-lasting outbreaks despite high levels of national vaccine coverage. The elimination status defined by the World Health Organization aims to identify countries where the virus is no longer circulating and can be verified after 36 months of interrupted transmission. However, since 2018, numerous countries have lost their elimination status soon after reaching it, showing that the indicators defining elimination may not be associated with lower risks of outbreaks.

Methods

We quantified the impact of local vaccine coverage and recent levels of incidence on the dynamics of measles in each French department between 2009 and 2018, using mathematical models based on the “Endemic-Epidemic” regression framework. After fitting the models using daily case counts, we simulated the effect of variations in the vaccine coverage and recent incidence on future transmission.

Results

High values of local vaccine coverage were associated with fewer imported cases and lower risks of local transmissions, but regions that had recently reported high levels of incidence were also at a lower risk of local transmission. This may be due to additional immunity accumulated during recent outbreaks. Therefore, the risk of local transmission was not lower in areas fulfilling the elimination criteria. A decrease of 3% in the 3-year average vaccine uptake led to a fivefold increase in the average annual number of cases in simulated outbreaks.

Conclusions

Local vaccine uptake was a reliable indicator of the intensity of transmission in France, even if it only describes yearly coverage in a given age group, and ignores population movements. Therefore, spatiotemporal variations in vaccine coverage, caused by disruptions in routine immunisation programmes, or lower trust in vaccines, can lead to large increases in both local and cross-regional transmission. The incidence indicator used to define the elimination status was not associated with a lower number of local transmissions in France, and may not illustrate the risks of imminent outbreaks. More detailed models of local immunity levels or subnational seroprevalence studies may yield better estimates of local risk of measles outbreaks.

Available only for authorised users

Gastañaduy PA, Budd J, Fisher N, Redd SB, Fletcher J, Miller J, et al. A measles outbreak in an underimmunized Amish community in Ohio. N Engl J Med. 2016;375:1343–54. https://doi.org/10.1056/NEJMoa1602295.CrossRefPubMed

Woudenberg T, Van Binnendijk RS, Sanders EAM, Wallinga J, De Melker HE, Ruijs WLM, et al. Large measles epidemic in the Netherlands, May 2013 to March 2014: Changing epidemiology. Eurosurveillance. 2017;22:1–9. https://doi.org/10.2807/1560-7917.ES.2017.22.3.30443.CrossRef

Funk S, Knapp JK, Lebo E, Reef SE, Dabbagh AJ, Kretsinger K, et al. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Med. 2019. https://doi.org/10.1186/s12916-019-1413-7.

Glasser JW, Feng Z, Omer SB, Smith PJ, Rodewald LE. The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study. Lancet Infect Dis. 2016;16:599–605. https://doi.org/10.1016/S1473-3099(16)00004-9.CrossRefPubMedPubMedCentral

Keenan A, Ghebrehewet S, Vivancos R, Seddon D, MacPherson P, Hungerford D. Measles outbreaks in the UK, is it when and where, rather than if? A database cohort study of childhood population susceptibility in Liverpool, UK. BMJ Open. 2017;7. https://doi.org/10.1136/bmjopen-2016-014106.

WHO. Global Vaccine Action Plan 2011-2020. Geneva: World Health Organization; 2013. https://www.who.int/publications/i/item/global-vaccine-action-plan-2011-2020. Accessed 3 Feb 2022.

World Health Organization. Framework for verifying elimination of measles and rubella. Wkly Epidemiol Rec. 2013;88:89–100. https://doi.org/10.1371/jour.CrossRef

World Health Organization (WHO). European Region loses ground in effort to eliminate measles 2019.

Pan American Health Organization / World Health Organization. Epidemiological Update: Measles. Washington, D.C: PAHO/WHO; 2018.

10.

Fraser B. Measles outbreak in the Americas. Lancet (London, England). 2018;392:373. https://doi.org/10.1016/S0140-6736(18)31727-6.CrossRef

11.

Litvoc MN, Lopes MIBF. From the measles-free status to the current outbreak in Brasil. Rev Assoc Med Bras. 2019;65:1229–30. https://doi.org/10.1590/1806-9282.65.10.1129.CrossRefPubMed

12.

Dimala CA, Kadia BM, Nji MAM, Bechem NN. Factors associated with measles resurgence in the United States in the post-elimination era. Sci Rep. 2021;11:1–10. https://doi.org/10.1038/s41598-020-80214-3.CrossRef

13.

Bernadou A, Astrugue C, Méchain M, Le Galliard V, Verdun-Esquer C, Dupuy F, et al. Measles outbreak linked to insufficient vaccination coverage in Nouvelle-Aquitaine region, France, October 2017 to July 2018. Eurosurveillance. 2018;23:1–5. https://doi.org/10.2807/1560-7917.ES.2018.23.30.1800373.CrossRef

14.

Held L, Höhle M, Hofmann M. A statistical framework for the analysis of multivariate infectious disease surveillance counts. Stat Model. 2005;5:187–99. https://doi.org/10.1191/1471082X05st098oa.CrossRef

15.

Meyer S, Held L, Höhle M. hhh4: Endemic-epidemic modeling of areal count time series. J Stat Softw. 2016;1:1-55.

16.

Lloyd-Smith JO, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual variation on disease emergence. Nature. 2005;438:355–9. https://doi.org/10.1038/nature04153.CrossRefPubMedPubMedCentral

17.

Fine PEM. The interval between successive cases of an infectious disease. Am J Epidemiol. 2003;158:1039–47. https://doi.org/10.1093/aje/kwg251.CrossRefPubMed

18.

Bjørnstad ON, Finkenstädt BF, Grenfell BT. Dynamics of measles epidemics: estimating scaling of transmission rates using a time series SIR model. Ecol Monogr. 2002;72:169–84. https://doi.org/10.1890/0012-9615(2002)072[0169:DOMEES]2.0.CO;2.CrossRef

19.

Bracher J, Held L. Endemic-epidemic models with discrete-time serial interval distributions for infectious disease prediction. Int J Forecast. 2020. https://doi.org/10.1016/j.ijforecast.2020.07.002.

20.

Woudenberg T, Woonink F, Kerkhof J, Cox K, Ruijs WLM. The tip of the iceberg : incompleteness of measles reporting during a large outbreak in The Netherlands in 2013 – 2014. Epidemiol Infect. 2018;146:716–22. https://doi.org/10.1017/S0950268818002698.CrossRef

21.

Lenormand M, Bassolas A, Ramasco JJ. Systematic comparison of trip distribution laws and models. J Transp Geogr. 2016;51:158–69. https://doi.org/10.1016/j.jtrangeo.2015.12.008.CrossRef

22.

Institut National de la Statistique et des Etudes Economiques. Estimation de la population au 1^er janvier 2020 2020. https://www.insee.fr/fr/statistiques/1893198#consulter (accessed 7 Sept 2020).

23.

Eurostat. European population grid cells. 2011. https://ec.europa.eu/eurostat/web/gisco/geodata/reference-data/grids (accessed 12 Sept 2020).

24.

Hijmans RJ, Etten J van, Mattiuzzi M, Sumner M, Greenberg JA, Lamigueiro OP, et al. Package “raster.” R 2014.

25.

Herzog SA, Paul M, Held L. Heterogeneity in vaccination coverage explains the size and occurrence of measles epidemics in German surveillance data. Epidemiol Infect. 2011;139:505–15. https://doi.org/10.1017/S0950268810001664.CrossRefPubMed

26.

Santé Publique France. Données départementales 2007-2012 de couverture vaccinale rougeole, rubéole, oreillons à 24 mois. 2019. https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-departementales-2007-2012-de-couverture-vaccinale-rougeole-rubeole-oreillons-a-24-mois. (accessed 7 Sept 2020).

27.

Santé Publique France. Estimations des couvertures vaccinales à 24 mois à partir des certificats de santé du 24e mois, 2004-2007. 2010. https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-departementales-2013-2017-de-couverture-vaccinale-rougeole-rubeole-oreillons-a-24-mois (accessed 7 Sept 2020).

28.

Santé Publique France. Données départementales 2013-2017 de couverture vaccinale rougeole, rubéole, oreillons à 24 mois. 2019. https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/articles/donnees-departementales-2013-2017-de-couverture-vaccinale-rougeole-rubeole-oreillons-a-24-mois (accessed 7 Sept 2020).

29.

Brooks ME, Kristensen K, van Benthem KJ, Magnusson A, Berg CW, Nielsen A, et al. glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. R J. 2017;9:378–400 https://doi.org/10.32614/rj-2017-066.CrossRef

30.

Antona D, Lévy-Bruhl D, Baudon C, Freymuth F, Lamy M, Maine C, et al. Measles elimination efforts and 2008-2011 outbreak, France. Emerg Infect Dis. 2013;19:357–64. https://doi.org/10.3201/eid1903.121360.CrossRefPubMedPubMedCentral

31.

Institut de Veille Sanitaire. Données de déclaration obligatoire de la rougeole. 2009. https://www.santepubliquefrance.fr/content/download/51424/1114368 (accessed 25 Jan 2022).

32.

Fitzpatrick G, Ward M, Ennis O, Johnson H, Cotter S, Carr MJ, et al. Use of a geographic information system to map cases of measles in real-time during an outbreak in Dublin, Ireland, 2011. Eurosurveillance. 2012;17:1–11. https://doi.org/10.2807/ese.17.49.20330-en.CrossRef

33.

Yang W, Wen L, Li SL, Chen K, Zhang WY, Shaman J. Geospatial characteristics of measles transmission in China during 2005−2014. PLoS Comput Biol. 2017;13:1–21. https://doi.org/10.1371/journal.pcbi.1005474.CrossRef

34.

Andrianou XD, Del Manso M, Bella A, Vescio MF, Baggieri M, Rota MC, et al. Spatiotemporal distribution and determinants of measles incidence during a large outbreak, Italy, september 2016 to july 2018. Eurosurveillance. 2019;24:1–12. https://doi.org/10.2807/1560-7917.ES.2019.24.17.1800679.CrossRef

35.

Funk S, Camacho A, Kucharski AJ, Lowe R, Eggo RM, Edmunds WJ. Assessing the performance of real-time epidemic forecasts: a case study of Ebola in the Western Area region of Sierra Leone, 2014-15. PLoS Comput Biol. 2019;15:e1006785. https://doi.org/10.1371/journal.pcbi.1006785.CrossRefPubMedPubMedCentral

36.

Bosse NI, Abbott S, EpiForecasts FS. scoringutils: Utilities for Scoring and Assessing Predictions; 2020. https://doi.org/10.5281/zenodo.4618017.CrossRef

37.

Czado C, Gneiting T, Held L. Predictive Model Assessment for Count Data; 2009. p. 1254–61. https://doi.org/10.1111/j.1541-0420.2009.01191.x.CrossRef

38.

le Polain de Waroux O, Saliba V, Cottrell S, Young N, Perry M, Bukasa A, et al. Summer music and arts festivals as hot spots for measles transmission: experience from England and Wales, June to October 2016. Eurosurveillance. 2016;21:1–6 https://doi.org/10.2807/1560-7917.ES.2016.21.44.30390.

39.

Gautret P, Steffen R. Communicable diseases as health risks at mass gatherings other than Hajj: What is the evidence? Int J Infect Dis. 2016;47:46–52. https://doi.org/10.1016/j.ijid.2016.03.007.CrossRefPubMed

40.

Patel MK, Goodson JL, Alexander JP, Kretsinger K, Sodha SV, Steulet C. Progress Toward Regional Measles Elimination — Worldwide, 2000 – 2019, vol. 69; 2020. p. 1700–5.

41.

Ramsay M. A strategic framework for the elimination of measles in the European Region; 1997.

42.

Gay NJ. The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis. 2004;189:27–35. https://doi.org/10.1086/381592.CrossRef

43.

Public Health Wales. Rubella, Wales Measles and Elimination Task Group: Action Plan 2019-2021. 2021.

44.

Blumberg S, Enanoria WTA, Lloyd-Smith JO, Lietman TM, Porco TC. Identifying postelimination trends for the introduction and transmissibility of measles in the United States. Am J Epidemiol. 2014;179:1375–82. https://doi.org/10.1093/aje/kwu068.CrossRefPubMedPubMedCentral

45.

Saxena S, Skirrow H, Bedford H. Routine vaccination during covid-19 pandemic response. BMJ. 2020;369:m2392. https://doi.org/10.1136/bmj.m2392.CrossRefPubMed

46.

Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccines Immunother. 2021;17:400–7. https://doi.org/10.1080/21645515.2020.1804776.CrossRef

47.

Toffolutti V, McKee M, Melegaro A, Ricciardi W, Stuckler D. Austerity, measles and mandatory vaccination: cross-regional analysis of vaccination in Italy 2000-14. Eur J Public Health. 2019;29:123–7. https://doi.org/10.1093/eurpub/cky178.CrossRefPubMed

Title: The impact of local vaccine coverage and recent incidence on measles transmission in France between 2009 and 2018
Authors: Alexis Robert
Adam J. Kucharski
Sebastian Funk
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/s12916-022-02277-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The impact of local vaccine coverage and recent incidence on measles transmission in France between 2009 and 2018

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors

Comprehensive and integrative analyses identify TYW5 as a schizophrenia risk gene

Correction: The UK Coronavirus Job Retention Scheme and diet, physical activity, and sleep during the COVID-19 pandemic: evidence from eight longitudinal population surveys

Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor

Hesitancy for receiving regular SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis from the UK-REACH study

International surveillance study in acute spinal cord injury confirms viability of multinational clinical trials